UK unveils MenB, MenACWY immunisation programmes for meningococcal dis


Sign up online today & collaborate

or click here to find out more

UK unveils MenB, MenACWY immunisation programmes for meningococcal disease

Date: 22/06/2015

Health officials in the UK on Sunday announced that two new vaccination programmes will be introduced this summer to protect babies and young people against the meningococcal bacterium. In September, GlaxoSmithKline's meningococcal serogroup B (MenB) vaccine Bexsero will be given to babies starting at two months of age, followed by a second dose at four months and a booster at 12 months. The scheme, whose implementation had been delayed over cost disputes, is the first national MenB programme in the world.

In March, GlaxoSmithKline reached an agreement with the UK Department of Health to allow infants in the UK to receive Bexsero through the NHS immunisation schedule. Although pricing details were not disclosed, GlaxoSmithKline said at the time that the agreement offered "fair value for the NHS and allows a reasonable return" for the company. Last year, the Joint Committee on Vaccination and Immunisation (JCVI) issuedguidance recommending the addition of Bexsero to the immunisation programme for babies as of two months of age. Andrew Pollard, chair of the JCVI, noted that the introduction of the immunisation programme for meningitis B represents "a huge step forward in controlling childhood meningitis and septicaemia."

For more click here

Source: First Word Pharma

© Catalyst Innovation Portal 2019